About Foresite Capital
Foresite Capital is a venture capital firm founded in 2011. It is primarily based out of New York City, United States. As of Sep 2026, Foresite Capital is an active investor, having invested in 215 companies, with 10 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Post IPO round of Korsana Overall, Foresite Capital portfolio has seen 7 unicorns, 87 IPOs and 69 acquisitions including key companies like Hims, Natera and GRAIL. A lot of funds co-invest with Foresite Capital, with names like Orbimed sharing a substantial percentage of its portfolio. Foresite Capital has team of 19 people including 10 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Foresite Capital's List of Top Investments
Foresite Capital has a portfolio of 215 companies, including 7 unicorns. Their most notable investments are in Element Biosciences and Pharvaris.Their portfolio spans across United States, United Kingdom, Canada and 6 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 7 other sectors, across stages such as Series B, Series C and 7 more. Here is the list of top investments by Foresite Capital:
1. Hims
Online platform offering telehealth services for men's wellness. The company focuses on men's wellness and care, offering treatment options for hair loss, erectile dysfunction, and more.
Key facts about Hims
- Founded Year: 2017
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $197M
- Employee Count: 2,107 as on Sep 30, 2026
- Investors: Brentwood Associates, Foresite Capital and 17 Others
- Latest Funding Round: Post IPO, May 08, 2025, $*****
- Highlight: Public
2. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 6,034 as on Sep 30, 2026
- Investors: Harmony Partners, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public

3. GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Key facts about GRAIL
- Founded Year: 2016
- Location: Menlo Park (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $2B
- Employee Count: 1,141 as on Sep 30, 2026
- Investors: Foresite Capital, Gershon Capital and 52 Others
- Latest Funding Round: Post IPO, Jun 25, 2026, $*****
- Highlight: Public
4. 10X Genomics
Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis. The company develops instruments, consumables, and software that enable researchers to profile up to a million cells, map RNA and proteins in tissues, and support multiomics workflows, with products cited in publications.
Key facts about 10X Genomics
- Founded Year: 2012
- Location: Pleasanton (United States)
- Stage: Public
- Total Funding till date: $243M
- Employee Count: 2,525 as on Sep 30, 2026
- Investors: Sprout Capital Partners, Meritech and 14 Others
- Latest Funding Round: Series D, Jan 07, 2019, $*****
- Highlight: Public
5. iRhythm Tech
Provider of cloud-based cardiac rhythm monitoring devices. It provides Zio ambulatory ECG monitor a wearable patch designed to gather beat-to-beat heart data for the diagnosis of cardiac arrhythmias. The device stores data in the patch and is emailed to the iRhythm cloud at the end of the monitoring period. myZio iPhone app is an add-on for the Zio Patch for physicians to make a diagnosis.
Key facts about iRhythm Tech
- Founded Year: 2006
- Location: San Francisco (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $98.9M
- Employee Count: 1,909 as on Sep 30, 2026
- Investors: Foresite Capital, UNC Kenan-Flagler Private Equity and 12 Others
- Latest Funding Round: Series E, May 22, 2014, $*****
- Highlight: Public
Foresite Capital's Year-on-Year Investment Trends
Foresite Capital has invested in 216 companies over the last 14 years, with an average of 9 new investments annually in the last 10 years. In 2025, it made 9 investments, while as of Sep 2026, it has made 12 investments in this year. Its most recent first time investment was in Khartis Therapeutics and most recent follow-on round was in Korsana.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 5 | 12 |
2025 | 5 | 4 | 9 |
2024 | 11 | 7 | 18 |
2023 | 3 | 4 | 7 |
2022 | 7 | 8 | 15 |
2021 | 14 | 10 | 24 |
2020 | 21 | 12 | 33 |
2019 | 8 | 6 | 14 |
2018 | 13 | 3 | 16 |
2017 | 5 | 3 | 8 |
Foresite Capital's Investments by Stage
Foresite Capital has made 43 investments in Series B stage with an average round size of $65.2M, 26 investments in Series C stage with an average round size of $115M and 24 investments in Series A stage with an average round size of $87.9M.Stage of entry | No. of Investments |
|---|---|
Series B | 42 |
Series C | 26 |
Series A | 24 |
Post IPO | 10 |
Series D | 8 |
Others | 9 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Sector
Foresite Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 194 Tech companies, 184 Enterprise (B2B) companies, 32 Software companies and at least 18 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 102 |
High Tech | 26 |
HealthTech | 19 |
Enterprise Applications | 15 |
Sustainability Tech | 7 |
Others | 16 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Geography
Foresite Capital has made most investments in United States (107), followed by United Kingdom where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 107 |
United Kingdom | 6 |
Ireland | 2 |
China | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Foresite Capital's recent investments
Foresite Capital has made 12 investments in 2026 so far. Korsana and Thyme Care are the latest among them.Here are the most recent investments by Foresite Capital:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 10, 2026 | United States | Post IPO | 4457 | [+15] | |
Sep 02, 2026 | United States | Series E | 8945 | [+8] | |
Aug 13, 2026 | United States | Series B | 5415 | ||
Aug 07, 2026 | United States | Series D | 5699 | ||
Aug 05, 2026 | United States | Post IPO | 6757 |
Unicorns in Foresite Capital's Portfolio
Foresite Capital has 7 unicorns in its portfolio - Join Midi, Thyme Care, Element Biosciences and others. The most recent unicorn in their portfolio is Join Midi. It became a unicorn in 2026.Here is a list of unicorns in Foresite Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
67 | Provider of a virtual care platform focused on female midlife health | 2021 | Los Altos Hills | Series D | pleqjhj | ||
68 | Provider of home nursing care services | 2020 | Nashville | Series E | vgbezhq | ||
64 | Developer of benchtop DNA sequencer for research applications | 2017 | San Diego | Series E | vassddr | ||
64 | Provider of molecular diagnostics platform by using CRISPR technology | 2017 | Brisbane | Series D | b{sszaw | ||
60 | Provider of home-based diagnostic tests for the detection of various diseases | 2014 | Austin | Funding Raised | wyxgwyb |
IPOs and Publicly Listed companies in Foresite Capital's Portfolio
87 of Foresite Capital's portfolio companies have become public. Korsana got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2026 and Latigo Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.14B.Here are Foresite Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 09, 2026 | Feb 18, 2026 | Series A | 9068 | |
Aug 07, 2026 | Feb 14, 2024 | Series A | 9003 | |
Aug 04, 2026 | Apr 03, 2024 | Series C | 7149 | |
Jun 10, 2026 | Mar 01, 2024 | Series E | 8669 | |
May 08, 2026 | Dec 08, 2021 | Series A | 6727 |
Acquired companies in Foresite Capital's Portfolio
69 companies from Foresite Capital's portfolio have been acquired. The most recent acquisition was Kira Pharmaceuticals in Jul 2026 by Jasper Therapeutics for $*****.Here are Foresite Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 16, 2026 | Jan 07, 2021 | Series B | 7294 | |
Jun 17, 2026 | Apr 04, 2025 | Series A | 5846 | |
May 03, 2026 | Sep 09, 2024 | Series D | 9084 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 3222 | |
Dec 15, 2025 | Feb 27, 2018 | Series B | 4414 |
Team profile of Foresite Capital
Foresite Capital has a team of 19 members including 10 Partners located in United States. Foresite Capital's team sits on the board of 2 companies.Here is a list of top team members in Foresite Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | |||
Partner | San Francisco | |||
Partner | Denver | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | Denver | - | ||
Partner | - | - | ||
Partner | - | - |
Co-investors of Foresite Capital
Over the past 14 years, 923 investors have co-invested in Foresite Capital's portfolio companies. This includes funds and angels.
- Invested before Foresite Capital: HHS, Google Ventures and 364 others have invested in rounds before Foresite Capital. There are 14 companies where HHS has invested before Foresite Capital and 11 companies where Google Ventures has invested before Foresite Capital.
- Top Co-investors of Foresite Capital: 264 investors entered a company along with Foresite Capital. These include investors like Orbimed (19 companies).
- Invested after Foresite Capital: A total of 293 investors have invested in Foresite Capital's portfolio after their investments. Top Investors include RA Capital Management (9 companies), Fidelity Investments (8 companies) and Janus Henderson Investors (8 companies).
Recent News related to Foresite Capital
•
KymaThera Raises $80M Series B FundingFinSMEs•Oct 06, 2026•KymaThera, Alta Partners, Venrock, Foresite Capital and 1 other
•
Korsana Biosciences Completes Merger with Cyclerion Therapeutics and $380 Million Private PlacementGlobeNewswire•Sep 09, 2026•Korsana, Cyclerion, Venrock, General Atlantic and 14 others
•
Abcuro Secures $66 Million Series D Funding for IBM Clinical Trialhttps://www.clinicaltrialsarena.com/•Aug 19, 2026•Abcuro, New Leaf Venture Partners, Bain Capital Life Sciences, Aberdeen Group and 10 others
•
Khartis Therapeutics Raises $50M in Series B FundingFinSMEs•Aug 13, 2026•Nextech Invest, Forge Life Science Partners, Alexandria, Longwood Fund and 1 other
•
Stepful Announces $55M Series C to Scale Its AI-Powered Training Platform Across the Healthcare WorkforceTraining Industry•Jun 08, 2026•Education Impact Fund, Intermountain Healthcare, Stepful, SemperVirens and 5 others
•
Quince Acquires Orphai Therapeutics for Up to $187M, Advancing Pulmonary PipelineGlobeNewswire•May 18, 2026•OrphAI Therapeutics, Quince Therapeutics, Quince, Balyasny Asset Management and 12 others
•
Pinnacle raises an $89M series B for its oral peptide programsBioWorld•Mar 26, 2026•Pinnacle Medicines, LAV, Foresite Capital, Logos and 4 others
•
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseaseshttps://www.intelligence360.news/•Mar 12, 2026•Korsana, Fairmount Ventures, J.P. Morgan Asset Management, TCG Crossover and 5 others
•
Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache DisordersBusiness Wire•Feb 24, 2026•Slate Medicines, RA Capital Management, Foresite Capital, Forbion
•